Emergency Preparedness and Response

Animal Rule Summary

In assessing the sufficiency of animal data, the agency may take into account other data, including human data, available to the agency. Under this rule, FDA can rely on the evidence from animal studies to provide substantial evidence of the effectiveness of these products when:

  1. There is a reasonably well-understood pathophysiological mechanism for the toxicity of the chemical, biological, radiological, or nuclear substance and its amelioration or prevention by the product;
  2. The effect is demonstrated in more than one animal species expected to react with a response predictive for humans, unless the effect is demonstrated in a single animal species that represents a sufficiently well-characterized animal model (meaning the model has been adequately evaluated for its responsiveness) for predicting the response in humans;
  3. The animal study endpoint is clearly related to the desired benefit in humans, which is generally the enhancement of survival or prevention of major morbidity; and
  4. The data or information on the pharmacokinetics and pharmacodynamics of the product or other relevant data or information in animals and humans is sufficiently well-understood to allow selection of an effective dose in humans, and it is therefore reasonable to expect the effectiveness of the product in animals to be a reliable indicator of its effectiveness in humans.

All studies subject to this rule must be conducted in accordance with preexisting requirements under the good laboratory practices (21 CFR part 58disclaimer icon) regulations and the Animal Welfare Act (7 U.S.C. 2131 et. seq.disclaimer icon). Safety evaluation of products is not addressed in this rule. Products evaluated for effectiveness under subpart I of part 314disclaimer icon and subpart H of part 601disclaimer icon will be evaluated for safety under preexisting requirements for establishing the safety of new drug and biological products.

The agency believes that the safety of most of these products can be studied in human volunteers similar to the people who would be exposed to the product. FDA recognizes that some safety data, such as data on possible adverse interactions between the toxic substance itself and the new product, may not be available. This is not expected to keep the agency from making an adequate safety evaluation.

FDA’s procedures and standards for evaluating the safety of new drug and biological products are sufficiently flexible to provide for the safety evaluation of products evaluated for efficacy under 21 CFR subpart I of part 314 and subpart H of part 601. This rule will not apply if product approval can be based on standards described elsewhere in our regulations (e.g., accelerated approval based on human surrogate markers or clinical endpoints other than survival or irreversible morbidity).

This summary was taken from the introduction in the final regulation, New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible, Federal Register, Vol. 67, No. 105, Friday, May 31, 2002. (Federal Register noticedisclaimer icon)

See also: Revised Draft Guidance: Product Development Under the Animal Rule (PDF, 2 MB) and Animal Rule Information

Page Last Updated: 01/27/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.